Special Issue

Drug Discovery and Evaluation for Treatment of Autoimmune Diseases

Message from the Guest Editor

Over the past decade, for many autoimmune diseases there have been numerous successes in developing targeted therapies that have led to an improved range of choices for clinical treatment. The success of biological therapies for autoimmune diseases, coupled with rapid advances in basic research, has validated the targeting of many immunology-relevant signaling pathways and uncovered new intracellular molecules as potential new drug targets. However, there are still unmet clinical needs in these diseases. In autoimmune diseases, loss of B-cell or T-cell tolerance is frequently observed, and indeed, the human leukocyte antigen (HLA) locus is commonly associated with an increased risk of disease susceptibility. While a deep understanding of signaling pathways in autoimmune diseases is challenging, basic research is very informative for the development of new therapies. Thus, this Special Issue aims to address the pressing need for the development of new drugs or the repositioning of drugs based on a molecular and clinical understanding of the signaling pathways of autoimmune diseases in combination with high-throughput analysis of integrated datasets.

Guest Editor

Dr. Agnieszka Paradowska Gorycka

Department of Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Spartańska 1, 02-637 Warsaw, Poland

Deadline for manuscript submissions

closed (15 February 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/105647

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

